Table 2

Frequency of antifungal resistance among clinical isolates of Candida spp. by geographic region in the 2010-2011 SENTRY Surveillance Program

Candida speciesAntifungal agentNo. of isolates (% resistanta to each antifungal agent) by region
North AmericaEuropeLatin AmericaAsia-PacificTotal
C. albicansAnidulafungin503 (0.0)552 (0.0)186 (0.0)164 (0.0)1,405 (0.0)
Caspofungin503 (0.0)552 (0.4)186 (0.0)164 (0.6)1,405 (0.2)
Micafungin503 (0.0)552 (0.4)186 (0.0)164 (0.0)1,405 (0.1)
Fluconazole503 (0.6)552 (0.2)186 (0.0)164 (0.6)1,405 (0.4)
Posaconazolec503 (0.6)552 (8.3)186 (6.5)164 (0.6)1,405 (4.4)
Voriconazole503 (0.6)552 (0.2)186 (0.0)164 (0.6)1,405 (0.4)
C. glabrataAnidulafungin306 (1.6)175 (1.7)38 (0.0)52 (3.8)571 (1.8)
Caspofungin306 (1.6)175 (1.7)38 (0.0)52 (1.9)571 (1.6)
Micafungin306 (1.3)175 (1.1)38 (0.0)52 (1.9)571 (1.2)
Fluconazole306 (9.8)175 (6.3)38 (5.3)52 (13.5)571 (8.8)
Posaconazolec306 (3.3)175 (2.9)38 (5.3)52 (5.8)571 (3.5)
Voriconazoleb306 (11.1)175 (9.1)38 (7.9)52 (13.5)571 (10.5)
C. parapsilosisAnidulafungin173 (1.2)195 (0.0)104 (1.0)93 (0.0)565 (0.5)
Caspofungin173 (0.0)195 (0.0)104 (0.0)93 (0.0)565 (0.0)
Micafungin173 (0.0)195 (0.0)104 (0.0)93 (0.0)565 (0.0)
Fluconazole173 (0.0)195 (3.1)104 (1.0)93 (5.4)565 (2.1)
Posaconazolec173 (1.2)195 (0.5)104 (3.9)93 (6.5)565 (2.3)
Voriconazole173 (0.0)195 (0.0)104 (0.0)93 (1.1)565 (0.2)
C. tropicalisAnidulafungin109 (0.0)89 (0.0)76 (0.0)44 (0.0)318 (0.0)
Caspofungin109 (0.0)89 (0.0)76 (0.0)44 (0.0)318 (0.0)
Micafungin109 (0.0)89 (0.0)76 (0.0)44 (0.0)318 (0.0)
Fluconazole109 (2.7)89 (1.1)76 (0.0)44 (0.0)318 (1.3)
Posaconazolec109 (7.3)89 (7.9)76 (2.6)44 (0.0)318 (5.3)
Voriconazole109 (0.9)89 (0.0)76 (0.0)44 (0.0)318 (0.3)
C. kruseiAnidulafungin40 (0.0)28 (0.0)8 (0.0)3 (0.0)79 (0.0)
Caspofungin40 (0.0)28 (0.0)8 (0.0)3 (0.0)79 (0.0)
Micafungin40 (0.0)28 (0.0)8 (0.0)3 (0.0)79 (0.0)
Posaconazolec40 (17.5)28 (7.1)8 (25.0)3 (33.3)79 (15.2)
Voriconazole40 (2.5)28 (0.0)8 (0.0)3 (0.0)79 (1.3)
  • a Resistance is defined as an MIC of >0.5 μg/ml for anidulafungin, caspofungin, and micafungin against C. albicans, C. tropicalis, and C. krusei, an MIC of >4 μg/ml against C. parapsilosis, an MIC of >0.25 μg/ml for anidulafungin and caspofungin, and an MIC of >0.12 μg/ml for micafungin against C. glabrata; an MIC of >4 μg/ml for fluconazole against C. albicans, C. tropicalis, and C. parapsilosis, an MIC of >32 μg/ml against C. glabrata; and an MIC of >0.5 μg/ml for voriconazole against C. albicans, C. tropicalis, and C. parapsilosis.

  • b In lieu of clinical breakpoints for voriconazole against C. glabrata, the epidemiological cutoff value (ECV) of >0.5 μg/ml was used to identify non-wild-type (non-WT) isolates.

  • c Posaconazole ECVs were used to identify non-WT isolates of C. albicans (ECV > 0.06 μg/ml), C. glabrata (ECV > 2 μg/ml), C. parapsilosis (ECV > 0.25 μg/ml), C. tropicalis (ECV > 0.12 μg/ml), and C. krusei (ECV > 0.5 μg/ml).